Phosphorylation Regulates Myc Expression Via Prolonged Activation of the Mitogen-activated Protein Kinase Pathway
Overview
Physiology
Authors
Affiliations
We previously showed that prolonged and strong ERK phosphorylation induced by Compound 5 (Cpd 5), a Cdc25A protein phosphatase inhibitor, was involved in its mechanism of cell growth inhibition. To study the relationship between ERK phosphorylation and cell growth inhibition, we used Cpd 5 as a tool to investigate ERK-regulated c-Myc expression in Hep3B hepatoma cells. We found that ERK phosphorylation caused by Cpd 5 induced c-Myc phosphorylation, but suppressed c-Myc expression at the mRNA and protein levels. Furthermore, Cpd 5 inhibited c-Myc transcriptional activity and DNA binding ability, and this inhibition was antagonized by ERK kinase (MEK) inhibitor U-0126, implying that the ERK pathway was involved in regulating c-Myc expression. Since the participation of c-Myc protein in transcription requires its dimerization with Max protein, we examined the Myc-Max association in Cpd 5-treated cells and found that Cpd 5 suppressed Myc-Max dimerization. Transfection of Hep3B cells with mutated ERK (T188A/Y190F), which has lost its dual-phosphorylation sites, attenuated the actions of Cpd 5 on Myc-Max association. To further demonstrate whether Myc phosphorylation by Cpd 5-induced ERK activation was able to directly regulate c-myc gene expression, a chromatin immunoprecipitation (ChIP) assay was used to examine the binding of phospho-Myc to the c-myc promoter region. We found that phospho-Myc induced by Cpd 5 had lost its ability to bind to the c-myc promoter, whereas MEK inhibitor U-0126 antagonized this inhibitory effect. These data suggest that an increase in c-Myc phosphorylation in response to prolonged ERK phosphorylation negatively auto-regulates c-Myc gene expression, leading to the suppression of its target gene expression and cell cycle block.
Figueira M, Marques R, Cardoso H, Fonseca L, Duarte A, Silvestre S Int J Mol Sci. 2024; 25(22).
PMID: 39596074 PMC: 11593390. DOI: 10.3390/ijms252212006.
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo.
Yu Y, Zhao Y, Choi J, Shi Z, Guo L, Elizarraras J Cancers (Basel). 2022; 14(22).
PMID: 36428626 PMC: 9688897. DOI: 10.3390/cancers14225534.
Wieczfinska J, Pawliczak R Int J Mol Sci. 2022; 23(15).
PMID: 35955554 PMC: 9368845. DOI: 10.3390/ijms23158413.
Signal-induced PARP1-Erk synergism mediates IEG expression.
Cohen-Armon M, Yeheskel A, Pascal J Signal Transduct Target Ther. 2019; 4:8.
PMID: 30993015 PMC: 6459926. DOI: 10.1038/s41392-019-0042-0.
Guan F, Yang X, Li J, Dong W, Zhang X, Liu N J Am Heart Assoc. 2018; 8(1):e009871.
PMID: 30563421 PMC: 6405704. DOI: 10.1161/JAHA.118.009871.